Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer

被引：0
|
作者：
Huang Xiaomei [1 ]
Liu Zaiyi [2 ]
机构：
[1] Southern Med Univ, Sch Clin Med 2, Guangzhou, Peoples R China
[2] Guangdong Acad Med Sci, Dept Radiol, Guangdong Prov Peoples Hosp, 106 Zhongshan Er Rd, Guangzhou 510080, Peoples R China
来源：
JAMA ONCOLOGY | 2022年 / 8卷 / 04期
关键词：
D O I：
10.1001/jamaoncol.2021.7997
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：645 / 646
页数：1
相关论文
共 50 条
  • [31] The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy
    Xin Xu
    Wei Zhao
    Cuicui Liu
    Yongsheng Gao
    Dawei Chen
    Meng Wu
    Chao Li
    Xinzhao Wang
    Xiang Song
    Jinming Yu
    Zhaoyun Liu
    Zhiyong Yu
    BMC Cancer, 24
  • [32] Time to Surgery Following Neoadjuvant Chemotherapy for Breast Cancer Impacts Residual Cancer Burden, Recurrence, and Survival
    Sutton, T. L.
    Schlitt, A.
    Gardiner, S. K.
    Johnson, N.
    Garreau, J. R.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S9 - S10
  • [33] Time to surgery following neoadjuvant chemotherapy for breast cancer impacts residual cancer burden, recurrence, and survival
    Sutton, Thomas L.
    Schlitt, Alexander
    Gardiner, Stuart K.
    Johnson, Nathalie
    Garreau, Jennifer R.
    JOURNAL OF SURGICAL ONCOLOGY, 2020, 122 (08) : 1761 - 1769
  • [34] Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis
    Ostoros, Gyula
    Hettle, Robert
    Georgoulia, Nefeli
    Berktas, Mehmet
    Chander, Pratibha
    Perez, Ignacio Diaz
    Couto, Anne-Marie
    Eichinger, Christian
    Field, Polly
    Morten, Peter
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (12) : 1305 - 1313
  • [35] Does hopelessness contribute to reduced chances of event-free survival from breast cancer?
    不详
    REPRODUCTIVE HEALTH MATTERS, 2000, 8 (15) : 181 - 181
  • [36] Biomarker Dynamics and Long-Term Treatment Outcomes in Breast Cancer Patients with Residual Cancer Burden after Neoadjuvant Therapy
    Holanek, Milos
    Selingerova, Iveta
    Fabian, Pavel
    Coufal, Oldrich
    Zapletal, Ondrej
    Petrakova, Katarina
    Kazda, Tomas
    Hrstka, Roman
    Poprach, Alexandr
    Zvarikova, Maria
    Bilek, Ondrej
    Svoboda, Marek
    DIAGNOSTICS, 2022, 12 (07)
  • [37] Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes (TILs) and residual cancer burden (RCB)
    Asano, Y.
    Kashiwagi, S.
    Goto, W.
    Takada, K.
    Takashima, T.
    Morisaki, T.
    Noda, S.
    Onoda, N.
    Ohsawa, M.
    Hirakawa, K.
    Ohira, M.
    CANCER RESEARCH, 2017, 77
  • [38] A new measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy.
    Symmans, W.
    Peintinger, F.
    Hatzis, C.
    Kuerer, H.
    Valero, V.
    Hennessy, B.
    Green, M.
    Singletary, E.
    Hortobagyi, G.
    Pusztai, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 12S - 12S
  • [39] Positive bone marrow biopsy is associated with a decreased event-free survival in patients with breast cancer
    Mascaro, A.
    Vitelli, C. E.
    Baldi, A.
    Farina, M.
    Amini, M.
    Piro, F.
    Fortunato, L.
    EJC SUPPLEMENTS, 2008, 6 (07): : 69 - 69
  • [40] Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030
    Parsons, H. A.
    Blewett, T.
    Chu, X.
    Sridhar, S.
    Santos, K.
    Xiong, K.
    Abramson, V. G.
    Patel, A.
    Cheng, J.
    Brufsky, A.
    Rhoades, J.
    Force, J.
    Liu, R.
    Traina, T. A.
    Carey, L. A.
    Rimawi, M. F.
    Miller, K. D.
    Stearns, V.
    Specht, J.
    Falkson, C.
    Burstein, H. J.
    Wolff, A. C.
    Winer, E. P.
    Tayob, N.
    Krop, I. E.
    Markrigiorgos, G. M.
    Golub, T. R.
    Mayer, E. L.
    Adalsteinsson, V. A.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 899 - 906
12345